MannKind | MNKD - Ebitda


MannKind reported $17.92M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Adma Biologics USD 58.74M 14.75M Sep/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD 17.92M 8.17M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD 19.36M 190.79M Dec/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Xencor USD -51.05M 55.28M Dec/2025